ESR1 and breast cancer: Several clinical studies have shown that 16α-[18F]-fluoro-17β-estradiol ([18F]FES) PET/CT has overall high sensitivity (82–84%) and specificity (93–98%) rates [41], making it an interesting ER-targeting PET tracer to compare with FDG for the staging of patients with grade 1–2, ER + BC.